Cargando…

Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease

Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in patients with COVID‐19 with chronic liver diseases. We described the clinical features in patients with COVID‐19 with nonalcoholic fatty liver di...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Rui, Zhu, Li, Wang, Jian, Xue, Leyang, Liu, Longgen, Yan, Xuebing, Huang, Songping, Li, Yang, Yan, Xiaomin, Zhang, Biao, Xu, Tianmin, Li, Chunyang, Ji, Fang, Ming, Fang, Zhao, Yun, Cheng, Juan, Wang, Yinling, Zhao, Haiyan, Hong, Shuqin, Chen, Kang, Zhao, Xiang‐an, Zou, Lei, Sang, Dawen, Shao, Huaping, Guan, Xinying, Chen, Xiaobing, Chen, Yuxin, Wei, Jie, Zhu, Chuanwu, Wu, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436597/
https://www.ncbi.nlm.nih.gov/pubmed/32838108
http://dx.doi.org/10.1002/hep4.1592
_version_ 1783572534809067520
author Huang, Rui
Zhu, Li
Wang, Jian
Xue, Leyang
Liu, Longgen
Yan, Xuebing
Huang, Songping
Li, Yang
Yan, Xiaomin
Zhang, Biao
Xu, Tianmin
Li, Chunyang
Ji, Fang
Ming, Fang
Zhao, Yun
Cheng, Juan
Wang, Yinling
Zhao, Haiyan
Hong, Shuqin
Chen, Kang
Zhao, Xiang‐an
Zou, Lei
Sang, Dawen
Shao, Huaping
Guan, Xinying
Chen, Xiaobing
Chen, Yuxin
Wei, Jie
Zhu, Chuanwu
Wu, Chao
author_facet Huang, Rui
Zhu, Li
Wang, Jian
Xue, Leyang
Liu, Longgen
Yan, Xuebing
Huang, Songping
Li, Yang
Yan, Xiaomin
Zhang, Biao
Xu, Tianmin
Li, Chunyang
Ji, Fang
Ming, Fang
Zhao, Yun
Cheng, Juan
Wang, Yinling
Zhao, Haiyan
Hong, Shuqin
Chen, Kang
Zhao, Xiang‐an
Zou, Lei
Sang, Dawen
Shao, Huaping
Guan, Xinying
Chen, Xiaobing
Chen, Yuxin
Wei, Jie
Zhu, Chuanwu
Wu, Chao
author_sort Huang, Rui
collection PubMed
description Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in patients with COVID‐19 with chronic liver diseases. We described the clinical features in patients with COVID‐19 with nonalcoholic fatty liver disease (NAFLD). Confirmed patients with COVID‐19 from hospitals in 10 cities of Jiangsu Province, China, were retrospectively included between January 18, 2020, and February 26, 2020. The hepatic steatosis index (HSI) was used to defined NAFLD. A total of 280 patients with COVID‐19 were enrolled. Eighty‐six (30.7%) of 280 patients with COVID‐19 were diagnosed as NAFLD by HSI. One hundred (35.7%) patients presented abnormal liver function on admission. The median alanine aminotransferase (ALT) levels (34.5 U/L vs. 23.0 U/L; P < 0.001) and the proportion of elevated ALT (>40 U/L) (40.7% vs. 10.8%; P < 0.001) were significantly higher in patients with NAFLD than in patients without NAFLD on admission. The proportion of elevated ALT in patients with NAFLD was also significantly higher than patients without NAFLD (65.1% vs. 38.7%; P < 0.001) during hospitalization. Multivariate analysis showed that age over 50 years (odds ratio [OR], 2.077; 95% confidence interval [CI], 1.183, 3.648; P = 0.011) and concurrent NAFLD (OR, 2.956; 95% CI, 1.526, 5.726; P = 0.001) were independent risk factors of ALT elevation in patients with COVID‐19, while the atomized inhalation of interferon α‐2b (OR, 0.402; 95% CI, 0.236, 0.683; P = 0.001) was associated with a reduced risk of ALT elevation during hospitalization. No patient developed liver failure or death during hospitalization. The complications and clinical outcomes were comparable between patients with COVID‐19 with and without NAFLD. Conclusion: Patients with NAFLD are more likely to develop liver injury when infected by COVID‐19. However, no patient developed severe liver‐related complications during hospitalization.
format Online
Article
Text
id pubmed-7436597
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74365972020-08-19 Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease Huang, Rui Zhu, Li Wang, Jian Xue, Leyang Liu, Longgen Yan, Xuebing Huang, Songping Li, Yang Yan, Xiaomin Zhang, Biao Xu, Tianmin Li, Chunyang Ji, Fang Ming, Fang Zhao, Yun Cheng, Juan Wang, Yinling Zhao, Haiyan Hong, Shuqin Chen, Kang Zhao, Xiang‐an Zou, Lei Sang, Dawen Shao, Huaping Guan, Xinying Chen, Xiaobing Chen, Yuxin Wei, Jie Zhu, Chuanwu Wu, Chao Hepatol Commun Original Articles Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in patients with COVID‐19 with chronic liver diseases. We described the clinical features in patients with COVID‐19 with nonalcoholic fatty liver disease (NAFLD). Confirmed patients with COVID‐19 from hospitals in 10 cities of Jiangsu Province, China, were retrospectively included between January 18, 2020, and February 26, 2020. The hepatic steatosis index (HSI) was used to defined NAFLD. A total of 280 patients with COVID‐19 were enrolled. Eighty‐six (30.7%) of 280 patients with COVID‐19 were diagnosed as NAFLD by HSI. One hundred (35.7%) patients presented abnormal liver function on admission. The median alanine aminotransferase (ALT) levels (34.5 U/L vs. 23.0 U/L; P < 0.001) and the proportion of elevated ALT (>40 U/L) (40.7% vs. 10.8%; P < 0.001) were significantly higher in patients with NAFLD than in patients without NAFLD on admission. The proportion of elevated ALT in patients with NAFLD was also significantly higher than patients without NAFLD (65.1% vs. 38.7%; P < 0.001) during hospitalization. Multivariate analysis showed that age over 50 years (odds ratio [OR], 2.077; 95% confidence interval [CI], 1.183, 3.648; P = 0.011) and concurrent NAFLD (OR, 2.956; 95% CI, 1.526, 5.726; P = 0.001) were independent risk factors of ALT elevation in patients with COVID‐19, while the atomized inhalation of interferon α‐2b (OR, 0.402; 95% CI, 0.236, 0.683; P = 0.001) was associated with a reduced risk of ALT elevation during hospitalization. No patient developed liver failure or death during hospitalization. The complications and clinical outcomes were comparable between patients with COVID‐19 with and without NAFLD. Conclusion: Patients with NAFLD are more likely to develop liver injury when infected by COVID‐19. However, no patient developed severe liver‐related complications during hospitalization. John Wiley and Sons Inc. 2020-09-02 /pmc/articles/PMC7436597/ /pubmed/32838108 http://dx.doi.org/10.1002/hep4.1592 Text en © 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Huang, Rui
Zhu, Li
Wang, Jian
Xue, Leyang
Liu, Longgen
Yan, Xuebing
Huang, Songping
Li, Yang
Yan, Xiaomin
Zhang, Biao
Xu, Tianmin
Li, Chunyang
Ji, Fang
Ming, Fang
Zhao, Yun
Cheng, Juan
Wang, Yinling
Zhao, Haiyan
Hong, Shuqin
Chen, Kang
Zhao, Xiang‐an
Zou, Lei
Sang, Dawen
Shao, Huaping
Guan, Xinying
Chen, Xiaobing
Chen, Yuxin
Wei, Jie
Zhu, Chuanwu
Wu, Chao
Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease
title Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease
title_full Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease
title_fullStr Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease
title_full_unstemmed Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease
title_short Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease
title_sort clinical features of patients with covid‐19 with nonalcoholic fatty liver disease
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436597/
https://www.ncbi.nlm.nih.gov/pubmed/32838108
http://dx.doi.org/10.1002/hep4.1592
work_keys_str_mv AT huangrui clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT zhuli clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT wangjian clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT xueleyang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT liulonggen clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT yanxuebing clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT huangsongping clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT liyang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT yanxiaomin clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT zhangbiao clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT xutianmin clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT lichunyang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT jifang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT mingfang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT zhaoyun clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT chengjuan clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT wangyinling clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT zhaohaiyan clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT hongshuqin clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT chenkang clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT zhaoxiangan clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT zoulei clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT sangdawen clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT shaohuaping clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT guanxinying clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT chenxiaobing clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT chenyuxin clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT weijie clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT zhuchuanwu clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease
AT wuchao clinicalfeaturesofpatientswithcovid19withnonalcoholicfattyliverdisease